Please login to the form below

Not currently logged in
Email:
Password:

Scott Whitcup joins Questcor’s board of directors

Allergan’s chief scientific officer to help expand Acthar’s use to treat autoimmune conditions

Scott Whitcup - Questcor PharmaceuticalsScott Whitcup, executive VP of R&D and chief scientific officer at Amgen, has joined the board of directors at Questcor Pharmaceuticals.

The company said his experience in commericialising Botox as a treatment for chronic migraine, upper limb spasticity and neurogenic urologic conditions would be beneficial in Questcor's efforts to expand the uses of its own Acthar Gel brand to treat autoimmune conditions.

“The growth strategies and product manufacturing for Acthar and Botox have some interesting parallels,” said Questcor's chair, Virgil Thompson.

Acthar is currently approved in the US in several indications, including infantile spasms; exacerbations of multiple sclerosis in adults; nephrotic syndrome; and several rheumatic disorders including collagen diseases; dermatologic diseases and ophthalmic diseases.

Whitcup joined Allergan in 2000, becoming executive VP of R&D in 2004 and chief scientific officer in 2009.

Other products he has helped bring to market at Allergan include Lumigan, Restasis and Latisse.

Prior to joining Allergan Whitcup served as clinical director at the National Institutes of Health's National Eye Institute, where he help develop new therapies for ophthalmic diseases

22nd February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics